PMID- 27132810
OWN - NLM
STAT- MEDLINE
DCOM- 20170418
LR  - 20170418
IS  - 1804-7521 (Electronic)
IS  - 1213-8118 (Linking)
VI  - 160
IP  - 4
DP  - 2016 Dec
TI  - The impact of Angiotensin II Type 1 Receptor antibodies on morbidity and 
      mortality in Heart Mate II supported recipients.
PG  - 518-523
LID - 10.5507/bp.2016.025 [doi]
AB  - AIMS: One of the proposed limitations of left ventricular assist device (LVAD) 
      therapy is high degree of sensitization. Apart from human leukocyte antigen 
      (HLA), antibodies against Angiotensin II Type 1 Receptor (AT1R) have been 
      associated with adverse outcomes. The purpose of this study was to compare 
      complications and survival of anti - AT1R positive versus negative Heart Mate II 
      (HMII) recipients. METHODS: Altogether 96 patients received HMII at our 
      institution between 2008 and 2012. These were stratified into three groups: 
      antibody positive before implantation (AT1R+), antibody conversion during support 
      (AT1R-/+) and patients who remained antibody negative (AT1R-). Survival, major 
      on-device adverse events and post-transplant rejections were assessed with 
      Kaplan-Meier and log-rank tests. RESULTS: Two year on-device and overall survival 
      was 78 +/- 12% and 75 +/- 10% in AT1R-, 60 +/- 23% and 60 +/- 15% in AT1R+ and 92 +/- 6% 
      and 87 +/- 5% in AT1R-/+ group (P = 0.409, P = 0.185). Freedom from major adverse 
      event at two years for AT1R-, AT1R+ and AT1R-/+ was 49 +/- 14%, 53 +/- 16% and 41 +/- 
      11% (P = 0.875). Freedom from rejection was 63 +/- 17% in patients who were both 
      anti-AT1R and HLA negative and 65 +/- 13% in those who were antibody positive (P = 
      0.788). CONCLUSION: Patients who were anti-AT1R antibody positive had similar 
      on-device survival and rate of complications in comparison to those who were 
      antibody negative. In transplanted patients, there were no differences in the 
      overall survival and rejection between the groups.
FAU - Marian, Urban
AU  - Marian U
AD  - Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, 
      Prague, Czech Republic.
FAU - Slavcev, Antonij
AU  - Slavcev A
AD  - Department of Clinical Immunology, Institute for Clinical and Experimental 
      Medicine, Prague, Czech Republic.
FAU - Gazdic, Tomas
AU  - Gazdic T
AD  - Department of Cardiology, Institute for Clinical and Experimental Medicine, 
      Prague, Czech Republic.
FAU - Ivak, Peter
AU  - Ivak P
AD  - Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, 
      Prague, Czech Republic.
FAU - Netuka, Ivan
AU  - Netuka I
AD  - Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, 
      Prague, Czech Republic.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20160427
PL  - Czech Republic
TA  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
JT  - Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, 
      Czechoslovakia
JID - 101140142
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
RN  - 0 (Receptor, Angiotensin, Type 1)
SB  - IM
MH  - Adult
MH  - Antibodies/*metabolism
MH  - Female
MH  - Graft Rejection/immunology
MH  - HLA Antigens/immunology
MH  - Heart Failure/immunology/mortality/*therapy
MH  - Heart Transplantation/mortality
MH  - Heart-Assist Devices/*adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nervous System Diseases/etiology/mortality
MH  - Postoperative Hemorrhage/etiology
MH  - Prosthesis Failure
MH  - Prosthesis-Related Infections/etiology/mortality
MH  - Receptor, Angiotensin, Type 1/*immunology
MH  - Transplantation Immunology/immunology
OTO - NOTNLM
OT  - Angiotensin II Type 1 Receptor
OT  - Heart Mate II
OT  - LVAD
OT  - heart transplantation
EDAT- 2016/05/03 06:00
MHDA- 2017/04/19 06:00
CRDT- 2016/05/03 06:00
PHST- 2016/02/01 00:00 [received]
PHST- 2016/04/19 00:00 [accepted]
PHST- 2016/05/03 06:00 [pubmed]
PHST- 2017/04/19 06:00 [medline]
PHST- 2016/05/03 06:00 [entrez]
AID - 10.5507/bp.2016.025 [doi]
PST - ppublish
SO  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Dec;160(4):518-523. 
      doi: 10.5507/bp.2016.025. Epub 2016 Apr 27.